PFIZER INC.

Applied Therapeutics appoints John H. Johnson as Executive Chairman, with Dr. Shoshana Shendelman stepping down as CEO and Les Funtleyder named Interim CEO. The company faces challenges including a Complete Response Letter for govorestat's NDA in Classic Galactosemia and withdrawal of the European MAA. The NDA submission for govorestat in SORD Deficiency is delayed until after Q1 2025. Johnson received inducement awards including options for 2,000,000 shares and 1,000,000 restricted stock units.

Two years after Dobbs vs Jackson Women’s Health, abortion rights uncertainty rises with Trump’s return. The issue explores US abortion restrictions’ impact on clinical trials, Pfizer’s management against activist investor Starboard, and Eli Lilly’s UK investment. The edition also features a pharma event guide for 2025.

Precision medicine startup Promise Bio emerged from stealth with an $8.3 million seed investment led by Awz Ventures, supported by AION Labs, AstraZeneca, and Pfizer. The company received a grant from the Israel Innovation Authority. Promise Bio offers a cloud-based platform for epiproteomic analysis in precision medicine, focusing on immune-mediated diseases. The funds will accelerate development of its computational platform using epiproteomics and AI for predicting patient treatment responses and supporting drug R&D.

Rising ACR20 response rates in placebo arms of rheumatoid arthritis trials may be linked to global recruitment shifts, with recent trials including more patients from less affluent countries.

The 'Macular Edema - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers an overview of global clinical trials on Macular Edema, including trial numbers, enrollment, regions, countries, phases, statuses, and sponsor types. It highlights prominent drugs and companies involved, and provides enrollment trends and recent news.

David Epstein, after selling Seagen to Pfizer, joined Francesco de Rubertis' startup Ottimo Pharma, developing a cancer drug targeting PD-1 and VEGF pathways. Ottimo raised $140 million, aiming to outperform Keytruda and other immunotherapies, with a unique bifunctional antibody design.

5 studies, reported in 5 papers and 1 NIHR Report, included in the review. 539 participants, often from ethnic minorities or vulnerable communities, discussed motivations and barriers to COVID-19 vaccine trial participation. Themes included personal gains, perceived risk, family influence, community contribution, institutional trust, and trial accessibility.

Durvalumab improved progression-free survival (PFS) over placebo in patients with locally advanced, unresectable non–small cell lung cancer (NSCLC) after platinum-based chemoradiotherapy (CRT), with a 25% reduction in risk of disease progression or death. Subgroup analysis showed consistent PFS benefit regardless of CRT type, and a trend toward improved overall survival (OS) was observed. PACIFIC-5 supports consolidation immunotherapy after either concurrent or sequential CRT.

The 'Myositis - Pipeline Insight, 2024' report by ResearchAndMarkets.com offers insights into 18+ companies and 20+ pipeline drugs for Myositis, covering drug profiles, therapeutic assessments, and pipeline development activities.

Promise Bio emerges from stealth with $8.3M seed investment to accelerate its computational platform using epiproteomics and AI for immune-mediated disease treatment. The platform, developed from foundational research by Dr. Assaf Kacen and Prof. Yifat Merbl, profiles post-translational modifications from mass-spectrometry data. The funding, led by Awz Ventures and AION Labs, aims to advance precision medicine and build the world’s largest PTM database.